Journal of Literature Pharmacy Sciences

Yeni İn Vitro Deri Doku Modelleri ve Deri İkameleri
New In Vitro Skin Tissue Models and Skin Substitutes
Sena ERKANa, Selinay Başak ERDEMLİ KÖSEb,c, Suna SABUNCUOĞLUc, Pınar ERKEKOĞLUc
aTOBB Üniversitesi Mühendislik Fakültesi, Biyomedikal Mühendisliği Bölümü, Ankara, TÜRKİYE
bBurdur Mehmet Akif Ersoy Üniversitesi Fen Edebiyat Fakültesi, Kimya Bölümü, Burdur, TÜRKİYE
cHacettepe Üniversitesi Eczacılık Fakültesi, Farmasötik Toksikoloji ABD, Ankara, TÜRKİYE
J Lit Pharm Sci. 2021;10(2):198-210
doi: 10.5336/pharmsci.2020-78670
Article Language: TR
Full Text
ÖZET
 Deri; tüm mekanik hasarlara, fiziksel, kimyasal ve biyolojik ajanlara karşı vücudun koruyucu kalkanı olup, insan vücudunda termoregülasyon ve sıvı elektrolit dengesinin korunması da dâhil birçok hayati işlevin sürdürülmesinde önemli rol oynamaktadır. İnsan derisinin koruyucu özelliği oldukça yüksektir. Yanıklar, diyabetik ayak ülserleri, travmalara bağlı yaralanmalar ya da doğuştan gelen deride hasar ve nekrozlara sebep olan anomaliler, sonradan oluşan patolojiler deri bütünlüğünün bozulmasına yol açarak bu önemli fonksiyonların ve vücudun ilk savunma hattının sekteye uğramasına neden olabilirler. Sağlıklı deri, bazal membranda bulunan rejenerasyon yeteneğine sahiptir ve proliferatif kök hücreler aracılığıyla epidermis hasarını yenileme yeteneğine sahiptir. Ancak daha derin yaralanmalarda bu yenilenme gerçekleşemez. Derinin, doğal işlevini ve yapısını sürdürebilmesi için derinin bütünlüğünün sağlanması gereklidir ve bu amaçla günümüzde çok çeşitli deri ikameleri geliştirilmektedir. Doku mühendisliğindeki gelişmelerle, birçok doku modellemesi yapılmakta, çeşitli ilaç ve ksenobiyotiklerin dermal toksisitelerinin belirlenmesinde bu modeller kullanmaktadır. Bu sayede in vivo testlerde kullanılacak deney hayvanları sayısının azalması da mümkün olmaktadır. Ayrıca bu doku modelleri sayesinde deride etnik özelliklerin değerlendirilmesi, deri hassasiyeti, alerjik reaksiyonlar, deri kanserleri, yaşlanma, deri mikrobiyotasının incelenmesi gibi pek çok konuda araştırmalar yapılabilmektedir. Bu derlemede, eski ve yeni doku modelleri, bu doku modellerinin avantajları, dezavantajları, deri ikameleri, kullanım alanları ve olası istenmeyen etkileri hakkında bilgi vermek amaçlanmıştır.

Anahtar Kelimeler: Deri doku modelleri; deri ikameleri; deri greftleri
ABSTRACT
 The skin is the body's protective shield against mechanical injuries, physical chemical, and biological agents; plays an important role in maintenance many vital functions in the human body, including thermoregulation and fluid-electrolyte balance. Protective characteristics of human skin are very high. Different factors such as burns, diabetic foot ulcers, traumatic injuries or congenital anomalies causing skin damage/necrosis or secondary pathologies may cause disruption of skin integrity and interruption of these important functions and the body's first line of defense. Healthy skin has ability to regenerate epidermis damage through proliferative stem cells and it has regeneration ability located in basal membrane. However, this regeneration cannot occur in deeper injuries. For maintaining its natural function and structure, it is necessary to provide integrity of the skin. For this purpose, wide variety of skin substitutes are currently being developed. With advances in tissue engineering, many tissuemodeling studies are performed and these models are used to determine dermal toxicities of various drugs/xenobiotics. In this way, it is possible to reduce number of experimental animals for in vivo tests. In addition, thanks to these tissue models, several research can be carried out on many subjects such as evaluation of ethnic characteristics of skin, skin sensitivity, allergic reactions, skin cancers, aging, and examination of skin microbiota. In this review, we aim to give information about old and new tissue models, advantages and disadvantages of tissue models, skin substitutes, their utilization, and possible unwanted effects.

Keywords: Skin tissue models; skin substitutes; skin grafts
REFERENCES:
  1. The European Parliament and The Council of The European Union [İnternet]. [Erişim tarihi: 10.08.2020]. Regulation (EC) No 1223/2009 of The European Parliament and of The Council of 30 November 2009 on cosmetic products. Erişim linki: [Link] 
  2. Netzlaff F, Lehr CM, Wertz PW, Schaefer UF. The human epidermis models EpiSkin, SkinEthic and EpiDerm: an evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport. Eur J Pharm Biopharm. 2005;60(2):167-78. [Crossref] [PubMed] 
  3. Lee M, Hwang JH, Lim KM. Alternatives to In Vivo Draize Rabbit Eye and Skin Irritation Tests with a Focus on 3D Reconstructed Human Cornea-Like Epithelium and Epidermis Models. Toxicol Res. 2017;33(3):191-203. [Crossref] [PubMed] [PMC] 
  4. Rheinwald JG, Green H. Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes. Nature. 1977;265(5593):421-4. [Crossref] [PubMed] 
  5. Kandárová H, Leta?iová S. Alternative methods in toxicology: pre-validated and validated methods. Interdiscip Toxicol. 2011;4(3):107-13. [Crossref] [PubMed] [PMC] 
  6. Kandárová H, Hayden P, Klausner M, Kubilus J, Sheasgreen J. An in vitro skin irritation test (SIT) using the EpiDerm reconstructed human epidermal (RHE) model. J Vis Exp. 2009;(29):1366. [PubMed] [PMC] 
  7. Alrubaiy L, Al-Rubaiy KK. Skin substitutes: a brief review of types and clinical applications. Oman Med J. 2009;24(1):4-6. [PubMed] [PMC] 
  8. Vyas KS, Vasconez HC. Wound Healing: Biologics, Skin Substitutes, Biomembranes and Scaffolds. Healthcare (Basel). 2014;2(3):356-400. [Crossref] [PubMed] [PMC] 
  9. Monteiro IP, Shukla A, Marques AP, Reis RL, Hammond PT. Spray-assisted layer-by-layer assembly on hyaluronic acid scaffolds for skin tissue engineering. J Biomed Mater Res A. 2015;103(1):330-40. [Crossref] [PubMed] 
  10. De Wever B, Kurdykowski S, Descargues P. Human skin models for research applications in pharmacology and toxicology: Introducing NativeSkin®, the "missing link" bridging cell culture and/or reconstructed skin models and human clinical testing. Applied In Vitro Toxicology. 2015;1(1):26-32. [Crossref] 
  11. Poumay Y, Coquette A. Modelling the human epidermis in vitro: tools for basic and applied research. Arch Dermatol Res. 2007;298(8):361-9. [Crossref] [PubMed] [PMC] 
  12. Neupane R, Boddu SHS, Renukuntla J, Babu RJ, Tiwari AK. Alternatives to Biological Skin in Permeation Studies: Current Trends and Possibilities. Pharmaceutics. 2020;12(2):152. [Crossref] [PubMed] [PMC] 
  13. Liebsch M, Grune B, Seiler A, Butzke D, Oelgeschläger M, Pirow R, et al. Alternatives to animal testing: current status and future perspectives. Arch Toxicol. 2011;85(8):841-58. [Crossref] [PubMed] [PMC] 
  14. Choksi NY, Truax J, Layton A, Matheson J, Mattie D, Varney T, et al. United States regulatory requirements for skin and eye irritation testing. Cutan Ocul Toxicol. 2019;38(2):141-55. [Crossref] [PubMed] [PMC] 
  15. Mertsching H, Weimer M, Kersen S, Brunner H. Human skin equivalent as an alternative to animal testing. GMS Krankenhhyg Interdiszip. 2008;3(1):Doc11. [PubMed] [PMC] 
  16. Zhang Z, Michniak-Kohn BB. Tissue engineered human skin equivalents. Pharmaceutics. 2012;4(1):26-41. [Crossref] [PubMed] [PMC] 
  17. Ng WL, Yeong WY. The future of skin toxicology testing - Three-dimensional bioprinting meets microfluidics. Int J Bioprint. 2019;5(2.1):237. Erratum in: Int J Bioprint. 2020;6(4):309. [Crossref] [PubMed] [PMC] 
  18. EpiCS datasheet (Erişim Tarihi: 10.08.2020) [Link] 
  19. Ackermann K, Borgia SL, Korting HC, Mewes KR, Schäfer-Korting M. The Phenion full-thickness skin model for percutaneous absorption testing. Skin Pharmacol Physiol. 2010;23(2):105-12. [Crossref] [PubMed] 
  20. Wiegand C, Hewitt NJ, Merk HF, Reisinger K. Dermal xenobiotic metabolism: a comparison between native human skin, four in vitro skin test systems and a liver system. Skin Pharmacol Physiol. 2014;27(5):263-75. [Crossref] [PubMed] 
  21. Groeber F, Schober L, Schmid FF, Traube A, Kolbus-Hernandez S, Daton K, et al. Catch-up validation study of an in vitro skin irritation test method based on an open source reconstructed epidermis (phase II). Toxicol In Vitro. 2016;36:254-261. [Crossref] [PubMed] 
  22. Phenion [İnternet]. ©2020 Henkel AG & Co. KGaA [Erişim tarihi: 10.08.2020]. The Phenion® Open Source Reconstructed Epidermis [OS-REp] goes live! Erişim linki: [Link] 
  23. Alépée N, Bahinski A, Daneshian M, De Wever B, Fritsche E, Goldberg A, et al. State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. ALTEX. 2014;31(4):441-77. [Crossref] [PubMed] [PMC] 
  24. Groeber F, Engelhardt L, Lange J, Kurdyn S, Schmid FF, Rücker C, et al. A first vascularized skin equivalent as an alternative to animal experimentation. ALTEX. 2016;33(4):415-422. [Crossref] [PubMed] 
  25. Cellink Life Sciences [İnternet]. CELLINK 2021, All rights reserved [Erişim tarihi: 10.08.2020]. The skinny on bioprinting human skin. Erişim linki: [Link] 
  26. BioSpace [İnternet]. ©1985-2021 BioSpace.com [Erişim Tarihi: 10.08.2020]. Bioprinting advanced skin architecture complete with blood vessels using cellink technology. Erişim linki: [Link] 
  27. News medical life sciences [İnternet]. An AZoNetwork Site Owned and operated by AZoNetwork, © 2000-2021 [Erişim tarihi: 10.08.2020]. Labskin-3D human skin model for ethical testing. Erişim linki: [Link] 
  28. Harvey A, Cole LM, Day R, Bartlett M, Warwick J, Bojar R, et al. MALDI-MSI for the analysis of a 3D tissue-engineered psoriatic skin model. Proteomics. 2016;16(11-2):1718-25. [Crossref] [PubMed] [PMC] 
  29. El Ghalbzouri A, Siamari R, Willemze R, Ponec M. Leiden reconstructed human epidermal model as a tool for the evaluation of the skin corrosion and irritation potential according to the ECVAM guidelines. Toxicol In Vitro. 2008;22(5):1311-20. [Crossref] [PubMed] 
  30. Mathes SH, Ruffner H, Graf-Hausner U. The use of skin models in drug development. Adv Drug Deliv Rev. 2014;69-70:81-102. [Crossref] [PubMed] 
  31. Straticell [İnternet]. ©2020 - Straticell | designed with passion by weeb [Erişim tarihi: 10.08.2020]. In Vitro Skin Models.
  32. Suhail S, Sardashti N, Jaiswal D, Rudraiah S, Misra M, Kumbar SG. Engineered Skin Tissue Equivalents for Product Evaluation and Therapeutic Applications. Biotechnol J. 2019;14(7):e1900022. [Crossref] [PubMed] [PMC] 
  33. Nam KH, Smith AS, Lone S, Kwon S, Kim DH. Biomimetic 3D Tissue Models for Advanced High-Throughput Drug Screening. J Lab Autom. 2015;20(3):201-15. [Crossref] [PubMed] [PMC] 
  34. Pedrosa TDN, Catarino CM, Pennacchi PC, Assis SR, Gimenes F, Consolaro MEL, et al. A new reconstructed human epidermis for in vitro skin irritation testing. Toxicol In Vitro. 2017;42:31-37. [Crossref] [PubMed] 
  35. Lee JY, Lee J, Min D, Kim J, Kim HJ, No KT. Tyrosinase-Targeting Gallacetophenone Inhibits Melanogenesis in Melanocytes and Human Skin-Equivalents. Int J Mol Sci. 2020;21(9):3144. [Crossref] [PubMed] [PMC] 
  36. Pillaiyar T, Manickam M, Namasivayam V. Skin whitening agents: medicinal chemistry perspective of tyrosinase inhibitors. J Enzyme Inhib Med Chem. 2017;32(1):403-425. [Crossref] [PubMed] [PMC] 
  37. Mattek [İnternet]. ©2021 mattek all rights reserved [Erişim tarihi: 10.08.2020]. MelanoDerm?. Erişim linki: [Link] 
  38. epiCS (Erişim Tarihi: 10.08.2020) [Link] 
  39. Cell Systems [İnternet]. ©2020 Imprint - Privacy Policy [Erişim tarihi: 10.08.2020]. epiCS-M/Human Epidermis Equivalent with Melanocytes.
  40. EU Science Hub [İnternet]. [Erişim tarihi: 10.08.2020]. SAC Opinion on the validation study of the epiCS® Skin Irritation Test (SIT) based on the EURL ECVAM/ OECD Performance Standards for in vitro skin irritation testing using Reconstructed human Epidermis (RhE). Erişim linki: [Link] 
  41. Rasmussen C, Gratz K, Liebel F, Southall M, Garay M, Bhattacharyya S, et al. The StrataTest® human skin model, a consistent in vitro alternative for toxicological testing. Toxicol In Vitro. 2010;24(7):2021-9. [Crossref] [PubMed] 
  42. Gratz K, Rasmussen C, Corner A, Pirnstill S, Nataraj P, Simon S, Allen-Hoffman L. Utility of StrataTest (R), an in vitro human skin model, for skin irritancy and corrosivity assessments. Toxicology Letters. 2009;189:S85. [Crossref] 
  43. Bernard FX, Barrault C, Deguercy A, De Wever B, Rosdy M. Development of a highly sensitive in vitro phototoxicity assay using the SkinEthic reconstructed human epidermis. Cell Biol Toxicol. 2000;16(6):391-400. [Crossref] [PubMed] 
  44. Brohem CA, Cardeal LB, Tiago M, Soengas MS, Barros SB, Maria-Engler SS. Artificial skin in perspective: concepts and applications. Pigment Cell Melanoma Res. 2011;24(1):35-50. [Crossref] [PubMed] [PMC] 
  45. Jones PA, King AV, Earl LK, Lawrence RS. An assessment of the phototoxic hazard of a personal product ingredient using in vitro assays. Toxicol In Vitro. 2003;17(4):471-80. [Crossref] [PubMed] 
  46. Bayer M, Doucet O, Garcia NL, Marty JP, Zastrow L. Use of reconstituted human epidermis cultures to assess the disrupting effect of organic solvents on the barrier function of excised human skin. In Vitro and Molecular Toxicology. 2000;13(3):159-71. [Link] 
  47. Lago MEL, Cerqueira MT, Pirraco RP, Reis RL, Marques AP. Skin in vitro models to study dermal white adipose tissue role in skin healing. In: Marques AP, Pirraco RP, Cerqueira MT, Reis RL, eds. Skin Tissue Models. 1st ed. USA: Academic Press, Elsevier, Cambridge, MA; 2018. p. 327-52. [Crossref] 
  48. Cavo M, Fato M, Pe-uela L, Beltrame F, Raiteri R, Scaglione S. Microenvironment complexity and matrix stiffness regulate breast cancer cell activity in a 3D in vitro model. Sci Rep. 2016;6:35367. [Crossref] [PubMed] [PMC] 
  49. Randall MJ, Jüngel A, Rimann M, Wuertz-Kozak K. Advances in the Biofabrication of 3D Skin in vitro: Healthy and Pathological Models. Front Bioeng Biotechnol. 2018;6:154. [Crossref] [PubMed] [PMC] 
  50. Sakolish CM, Esch MB, Hickman JJ, Shuler ML, Mahler GJ. Modeling Barrier Tissues In Vitro: Methods, Achievements, and Challenges. EBioMedicine. 2016;5:30-9. [Crossref] [PubMed] [PMC] 
  51. Abaci HE, Guo Z, Doucet Y, Jacków J, Christiano A. Next generation human skin constructs as advanced tools for drug development. Exp Biol Med (Maywood). 2017;242(17):1657-68. [Crossref] [PubMed] [PMC] 
  52. Arnette C, Koetsier JL, Hoover P, Getsios S, Green KJ. In Vitro Model of the Epidermis: Connecting Protein Function to 3D Structure. Methods Enzymol. 2016;569:287-308. [Crossref] [PubMed] [PMC] 
  53. Nathoo R, Howe N, Cohen G. Skin substitutes: an overview of the key players in wound management. J Clin Aesthet Dermatol. 2014;7(10):44-8. [PubMed] [PMC] 
  54. Jeschke MG, van Baar ME, Choudhry MA, Chung KK, Gibran NS, Logsetty S. Burn injury. Nat Rev Dis Primers. 2020;6(1):11. [Crossref] [PubMed] [PMC] 
  55. Perez-Favila A, Martinez-Fierro ML, Rodriguez-Lazalde JG, Cid-Baez MA, Zamudio-Osuna MJ, Martinez-Blanco MDR, et al. Current Therapeutic Strategies in Diabetic Foot Ulcers. Medicina (Kaunas). 2019;55(11):714. [Crossref] [PubMed] [PMC] 
  56. Shpichka A, Butnaru D, Bezrukov EA, Sukhanov RB, Atala A, Burdukovskii V, et al. Skin tissue regeneration for burn injury. Stem Cell Res Ther. 2019;10(1):94. [Crossref] [PubMed] [PMC] 
  57. Genoskin ex vivo clinical testing [İnternet]. Genoskin ©2020 [Erişim tarihi: 10.08.2020]. Incospharm publishes results using NativeSkin®. Erişim linki: [Link] 
  58. Organogenesis [İnternet]. ©2020 Organogenesis Inc. [Erişim tarihi: 10.08.2020]. Apligraf. Erişim linki: [Link] 
  59. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging. 2007;2(1):93-8. [Crossref] [PubMed] [PMC] 
  60. Rodrigues M, Kosaric N, Bonham CA, Gurtner GC. Wound Healing: A Cellular Perspective. Physiol Rev. 2019;99(1):665-706. [Crossref] [PubMed] [PMC] 
  61. Hart CE, Loewen-Rodriguez A, Lessem J. Dermagraft: Use in the Treatment of Chronic Wounds. Adv Wound Care (New Rochelle). 2012;1(3):138-141. [Crossref] [PubMed] [PMC] 
  62. Li X, Xu G, Chen J. Tissue engineered skin for diabetic foot ulcers: a meta-analysis. Int J Clin Exp Med. 2015;8(10):18191-6. [PubMed] [PMC] 
  63. Santema TB, Poyck PP, Ubbink DT. Skin grafting and tissue replacement for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev. 2016;2(2):CD011255. [Crossref] [PubMed] [PMC] 
  64. Food and Drug Administration [İnternet]. [Erişim tarihi: 10.08.2020]. Summary of safety and effectiveness data. Erişim linki: [Link] 
  65. Savoji H, Godau B, Hassani MS, Akbari M. Skin Tissue Substitutes and Biomaterial Risk Assessment and Testing. Front Bioeng Biotechnol. 2018;6:86. [Crossref] [PubMed] [PMC] 
  66. Varkey M, Ding J, Tredget EE. Advances in Skin Substitutes-Potential of Tissue Engineered Skin for Facilitating Anti-Fibrotic Healing. J Funct Biomater. 2015;6(3):547-63. [Crossref] [PubMed] [PMC] 
  67. JAWSpodiatry [İnternet]. Copyright © 2020 JAWS Podiatry [Erişim tarihi: 10.08.2020]. TheraSkin Skin Graft Surgery. Erişim linki: [Link] 
  68. Wound Source. [İnternet]. © 2008-2021 Kestrel Health Information, Inc. [Erişim tarihi: 10.08.2020]. TheraSkin®. Erişim linki: [Link] 
  69. Horch RE, Jeschke MG, Spilker G, Herndon DN, Kopp J. Treatment of second degree facial burns with allografts--preliminary results. Burns. 2005;31(5):597-602. [Crossref] [PubMed] 
  70. Supp DM, Boyce ST. Engineered skin substitutes: practices and potentials. Clin Dermatol. 2005;23(4):403-12. [Crossref] [PubMed] 
  71. Shakespeare P, Shakespeare V. Survey: use of skin substitute materials in UK burn treatment centres. Burns. 2002;28(4):295-7. [Crossref] [PubMed] 
  72. Shakespeare PG. The role of skin substitutes in the treatment of burn injuries. Clin Dermatol. 2005;23(4):413-8. [Crossref] [PubMed] 
  73. Bello YM, Falabella AF, Eaglstein WH. Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol. 2001;2(5):305-13. [Crossref] [PubMed] 
  74. Leigh IM, Watt FM. The culture of human epidermal keratinocytes. In: Leigh I, Lane B, Watt F, eds. The keratinocyte handbook. 1st ed. UK/Cambridge: Cambridge University Press; 1994. p. 43-51.
  75. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell. 1975;6(3):331-43. [Crossref] [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com